ID   COLO 794
AC   CVCL_2408
SY   COLO-794; Colo 794; COLO #794; COLO794; Colorado 794
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472865
DR   cancercelllines; CVCL_2408
DR   Cell_Model_Passport; SIDM00514
DR   Cosmic; 972283
DR   DepMap; ACH-001339
DR   ECACC; 94072237
DR   EGA; EGAS00001000610
DR   ESTDAB; ESTDAB-001
DR   PharmacoDB; COLO794_218_2019
DR   Wikidata; Q54814153
RX   PubMed=15592718;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   HLA typing: A*02:01,29:02; B*44:02,44:03:01; C*05:01,16:01; DPB1*04:01,17:01; DQB1*03:01:01,02:01; DRB1*12:01,07:01 (PubMed=15592718).
CC   HLA typing: A*02:01,29:02; B*44:03,44:03; C*05:01,16:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Arg (c.403T>C); ClinVar=VCV000376560; Zygosity=Heterozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): DepMap; ECACC; ESTDAB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11,13
ST   D16S539: 11
ST   D18S51: 13,14
ST   D21S11: 29,30
ST   D3S1358: 18
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 14,15
ST   FGA: 23
ST   Penta D: 11,13
ST   Penta E: 7
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 16,20
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1135 ! COLO 800
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//